639 related articles for article (PubMed ID: 23595974)
1. Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors.
Carmina E; Campagna AM; Lobo RA
Hum Reprod; 2013 Aug; 28(8):2245-52. PubMed ID: 23595974
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
3. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
4. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
[TBL] [Abstract][Full Text] [Related]
5. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome.
Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY
Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907
[TBL] [Abstract][Full Text] [Related]
6. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
[TBL] [Abstract][Full Text] [Related]
7. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
Verit FF
Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset.
Espinós-Gómez JJ; Rodriguez-Espinosa J; Ordóñez-Llanos J; Calaf-Alsina J
Gynecol Endocrinol; 2012 Apr; 28(4):264-8. PubMed ID: 21962027
[TBL] [Abstract][Full Text] [Related]
9. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
[TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.
Sam S; Scoccia B; Yalamanchi S; Mazzone T
Hum Reprod; 2015 Jun; 30(6):1358-64. PubMed ID: 25857311
[TBL] [Abstract][Full Text] [Related]
11. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
Graff SK; Mário FM; Alves BC; Spritzer PM
Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
[TBL] [Abstract][Full Text] [Related]
12. The contribution of diet, physical activity and sedentary behaviour to body mass index in women with and without polycystic ovary syndrome.
Moran LJ; Ranasinha S; Zoungas S; McNaughton SA; Brown WJ; Teede HJ
Hum Reprod; 2013 Aug; 28(8):2276-83. PubMed ID: 23771201
[TBL] [Abstract][Full Text] [Related]
13. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters.
Carmina E; Chu MC; Longo RA; Rini GB; Lobo RA
J Clin Endocrinol Metab; 2005 May; 90(5):2545-9. PubMed ID: 15728203
[TBL] [Abstract][Full Text] [Related]
15. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.
Pinola P; Puukka K; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Lindén Hirschberg A; Ravn P; Skovsager Andersen M; Glintborg D; Mellembakken JR; Ruokonen A; Tapanainen JS; Morin-Papunen LC
Fertil Steril; 2017 Mar; 107(3):788-795.e2. PubMed ID: 28089571
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.
Ehrmann DA; Liljenquist DR; Kasza K; Azziz R; Legro RS; Ghazzi MN;
J Clin Endocrinol Metab; 2006 Jan; 91(1):48-53. PubMed ID: 16249284
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.
Rossi B; Sukalich S; Droz J; Griffin A; Cook S; Blumkin A; Guzick DS; Hoeger KM
J Clin Endocrinol Metab; 2008 Dec; 93(12):4780-6. PubMed ID: 18812482
[TBL] [Abstract][Full Text] [Related]
18. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome.
Vural B; Caliskan E; Turkoz E; Kilic T; Demirci A
Hum Reprod; 2005 Sep; 20(9):2409-13. PubMed ID: 15919774
[TBL] [Abstract][Full Text] [Related]
20. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
